User login
Key clinical point: Treatment with 15 mg or 30 mg upadacitinib demonstrated rapid and durable improvements in symptoms and quality of life in adults with moderate to severe atopic dermatitis (AD), based on a treat-to-target approach.
Major finding: Overall, >80%, >78%, and ≥87% of patients achieved the 3-month initial acceptable target, whereas ≥53%, >61%, and >73% of patients achieved the 6-month optimal target goal with 15 mg or 30 mg upadacitinib vs placebo at weeks 2, 16, and 52, respectively. The proportion of patients achieving a higher number of individual target criteria increased over time for both 3- and 6-month target goals.
Study details: This treat-to-target analysis of Measure Up 1 and Measure Up 2 phase 3 studies included 1282 adults with moderate to severe AD who were randomly assigned to receive 15 mg upadacitinib (n = 428), 30 mg upadacitinib (n = 424), or placebo (n = 430).
Disclosures: This study was funded by AbbVie. Five authors declared being employees of AbbVie or holding AbbVie stock, stock options, or patents. Several authors declared having ties with various sources, including AbbVie.
Source: Kwatra SG, de Bruin-Weller M, Silverberg JI, et al. Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis: A treat-to-target analysis of adults with moderate-to-severe atopic dermatitis treated with upadacitinib. Acta Derm Venereol. 2024;104:adv18452 (May 6). doi: 10.2340/actadv.v104.18452 Source
Key clinical point: Treatment with 15 mg or 30 mg upadacitinib demonstrated rapid and durable improvements in symptoms and quality of life in adults with moderate to severe atopic dermatitis (AD), based on a treat-to-target approach.
Major finding: Overall, >80%, >78%, and ≥87% of patients achieved the 3-month initial acceptable target, whereas ≥53%, >61%, and >73% of patients achieved the 6-month optimal target goal with 15 mg or 30 mg upadacitinib vs placebo at weeks 2, 16, and 52, respectively. The proportion of patients achieving a higher number of individual target criteria increased over time for both 3- and 6-month target goals.
Study details: This treat-to-target analysis of Measure Up 1 and Measure Up 2 phase 3 studies included 1282 adults with moderate to severe AD who were randomly assigned to receive 15 mg upadacitinib (n = 428), 30 mg upadacitinib (n = 424), or placebo (n = 430).
Disclosures: This study was funded by AbbVie. Five authors declared being employees of AbbVie or holding AbbVie stock, stock options, or patents. Several authors declared having ties with various sources, including AbbVie.
Source: Kwatra SG, de Bruin-Weller M, Silverberg JI, et al. Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis: A treat-to-target analysis of adults with moderate-to-severe atopic dermatitis treated with upadacitinib. Acta Derm Venereol. 2024;104:adv18452 (May 6). doi: 10.2340/actadv.v104.18452 Source
Key clinical point: Treatment with 15 mg or 30 mg upadacitinib demonstrated rapid and durable improvements in symptoms and quality of life in adults with moderate to severe atopic dermatitis (AD), based on a treat-to-target approach.
Major finding: Overall, >80%, >78%, and ≥87% of patients achieved the 3-month initial acceptable target, whereas ≥53%, >61%, and >73% of patients achieved the 6-month optimal target goal with 15 mg or 30 mg upadacitinib vs placebo at weeks 2, 16, and 52, respectively. The proportion of patients achieving a higher number of individual target criteria increased over time for both 3- and 6-month target goals.
Study details: This treat-to-target analysis of Measure Up 1 and Measure Up 2 phase 3 studies included 1282 adults with moderate to severe AD who were randomly assigned to receive 15 mg upadacitinib (n = 428), 30 mg upadacitinib (n = 424), or placebo (n = 430).
Disclosures: This study was funded by AbbVie. Five authors declared being employees of AbbVie or holding AbbVie stock, stock options, or patents. Several authors declared having ties with various sources, including AbbVie.
Source: Kwatra SG, de Bruin-Weller M, Silverberg JI, et al. Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis: A treat-to-target analysis of adults with moderate-to-severe atopic dermatitis treated with upadacitinib. Acta Derm Venereol. 2024;104:adv18452 (May 6). doi: 10.2340/actadv.v104.18452 Source